Dermatological Pharmacology: Eczema, Acne, Psoriasis and Drug Safety

Evidence and references reviewed: 10 November 2026.

Dermatological pharmacology includes topical and systemic treatment for inflammatory disease, acne and infections. Diagnosis determines the drug: treatment appropriate for eczema may be unsuitable for acne or a fungal eruption. Guidelines therefore provide different pathways for atopic dermatitis, acne and psoriasis.1,2,3

Cutaneous pharmacokinetics: the skin barrier matters

Topical drugs cross or act upon the stratum corneum, a lipid-rich barrier that limits penetration. Drug delivery depends on molecule size and lipophilicity, formulation, concentration, application site, skin integrity, occlusion and treatment duration. Ointments are often more occlusive than creams; gels, solutions and foams may be useful on hair-bearing or oily areas. Selecting a vehicle is part of the prescription, not merely a cosmetic preference.

Damaged or inflamed skin, large treatment areas and occlusion may increase systemic exposure. Facial, flexural, genital and pediatric skin often need lower-potency or steroid-sparing strategies; sustained potent topical corticosteroid use can cause skin atrophy, striae, telangiectasia and hypothalamic–pituitary–adrenal suppression in susceptible patients.4

Topical treatment and systemic exposure

Topical administration concentrates treatment at the skin but does not guarantee negligible absorption. Corticosteroid exposure depends on formulation, skin barrier, treated area, potency, duration and occlusion. Children can be especially susceptible to systemic toxicity. Excessive exposure to potent agents such as clobetasol can suppress the hypothalamic-pituitary-adrenal axis.4

Specify application site, frequency and duration. Several steroid-containing products can increase total exposure. Local adverse effects include irritation, striae, secondary infection and acneiform eruptions. Increasing steroid use without reassessment is not a reliable response to treatment failure.4

Dermatologic drug classes and mechanisms

Class Examples Mechanism Important caution
Topical corticosteroids Hydrocortisone, mometasone, clobetasol Glucocorticoid receptor-mediated suppression of inflammation. Potency-, site- and duration-dependent adverse effects; avoid indiscriminate facial use.
Calcineurin inhibitors Tacrolimus, pimecrolimus Reduce T-cell activation and inflammatory cytokine signaling. Burning sensation and label-specific warnings; not interchangeable with topical steroids.
Topical PDE4 inhibitors Crisaborole, roflumilast Increase cellular cAMP by inhibiting phosphodiesterase-4. Application irritation and product-specific age/site indications.
Topical JAK inhibitors Ruxolitinib cream Block JAK-mediated intracellular cytokine signaling. Use only within label constraints and with appropriate safety review.
Topical retinoids Adapalene, tretinoin, tazarotene Modulate RAR transcriptional pathways and follicular keratinization. Irritation and pregnancy-related contraindications/precautions.
Benzoyl peroxide 2.5–10% topical formulations Oxidative activity against Cutibacterium acnes. Dryness, irritation and bleaching of fabric.
Biologic agents Dupilumab, lebrikizumab, nemolizumab, IL-17/IL-23 inhibitors Target disease-specific inflammatory cytokines or receptors. Product-specific infection screening, monitoring, age and reimbursement restrictions.

A familiar drug class can have different indications by disease. For example, a JAK inhibitor used for atopic dermatitis is not automatically an appropriate acne treatment, and systemic IL-17 blockade for psoriasis is not interchangeable with a topical eczema treatment.1,2,3

Atopic dermatitis

Moisturizers and appropriately selected topical corticosteroids remain important. Topical calcineurin inhibitors, PDE4 inhibitors and JAK inhibitors offer additional options. Updated AAD guidance also includes newer treatments such as tapinarof and roflumilast. Selection depends on age, severity, site and product-specific authorization.1

Tacrolimus binds FKBP-12 and inhibits calcineurin-mediated T-cell activation; it is not a cyclosporine derivative. Its US ointment label specifies second-line, short-term or noncontinuous treatment in eligible patients. The boxed warning describes uncertain long-term safety and rare reported malignancies; causation has not been established. Neither presenting the warning as proof of cancer causation nor ignoring it accurately represents the label.5

More severe disease may need specialist biologic or systemic treatment. Guideline recommendations and regulatory approvals differ between countries. AAD guidance recommends against systemic corticosteroids for routine atopic-dermatitis management.1

2025 AAD update: newer atopic dermatitis therapy

The American Academy of Dermatology 2025 focused update added strong recommendations for selected adults with atopic dermatitis for topical tapinarof, topical roflumilast, the IL-13-directed antibody lebrikizumab, and nemolizumab with concomitant topical treatment. This supplements the earlier guideline-supported use of moisturizers, topical corticosteroids, calcineurin inhibitors, PDE4/JAK inhibitors and selected systemic biologics.1

Different agents target different pathways: lebrikizumab selectively blocks IL-13 signaling; nemolizumab antagonizes the IL-31 receptor alpha pathway involved in itch and inflammation; tapinarof is an aryl hydrocarbon receptor agonist; and roflumilast inhibits PDE4. Their approved age ranges, severity criteria, application schedules and national availability differ, so the guideline should not be mistaken for universal permission to prescribe all four together.

Systemic corticosteroids are generally discouraged for routine long-term atopic dermatitis control because of adverse effects and rebound. In selected difficult cases, a specialist may choose phototherapy or systemic treatment after reviewing skin infection, disease severity, prior responses, vaccination and patient preferences.1

Acne: combine mechanisms and limit antibiotics

Topical retinoids, benzoyl peroxide, azelaic acid and other selected agents address different components of acne. Limit systemic antibiotic exposure and combine it with benzoyl peroxide and appropriate topical treatment. Topical corticosteroids are not routine acne treatment, although clinicians may inject corticosteroids into selected inflammatory lesions. Severe, scarring or treatment-resistant disease may warrant oral isotretinoin.2

Isotretinoin is contraindicated in pregnancy and subject to US iPLEDGE risk-management requirements. Pregnancy testing and prevention requirements depend on reproductive potential; identical contraception requirements should not be assigned to everyone. Monitor relevant adverse effects and laboratory parameters according to the label and clinical circumstances. Avoid vitamin A supplements and tetracyclines; the latter combination raises concern about intracranial hypertension.6

2024 AAD acne guidance: avoid antibiotic monotherapy

The American Academy of Dermatology acne guideline strongly recommends benzoyl peroxide, topical retinoids and appropriately selected topical antibiotics, with combination regimens that address different pathogenic processes. Topical antibiotic monotherapy is not recommended, because resistance can emerge; combining an antibiotic with benzoyl peroxide helps reduce selection pressure.2,11

Oral antibiotics, such as selected tetracyclines, are used for appropriate moderate-to-severe inflammatory acne but should be time-limited and combined with topical therapy. Continuing oral antibiotics indefinitely is poor stewardship. Oral isotretinoin is effective for severe nodular, scarring or refractory acne but has major teratogenic and monitoring requirements and must not be combined casually with tetracyclines because of intracranial hypertension concerns.6

Clascoterone is a topical androgen-receptor inhibitor for selected acne patients. It should not be conflated with systemic spironolactone or isotretinoin; patient selection, product approval and pregnancy precautions differ. A prior topical retinoid and appropriate benzoyl peroxide regimen may be more suitable than immediate use of oral antibiotics.

Psoriasis: topical and systemic options

Treatment depends on extent, severity, site and patient factors. Options include topical corticosteroids and steroid-sparing agents, phototherapy, conventional systemic medicines and biologics. Methotrexate, cyclosporine, apremilast and acitretin differ in mechanism and monitoring; they are not interchangeable immunosuppressants.3

Methotrexate for psoriasis is normally taken weekly, not daily. Dosing errors can cause serious harm. Blood tests and monitoring for hepatic, hematologic and other toxicity are essential, with folic acid as appropriate. Patients must follow the exact regimen and report suspected adverse effects.7

Cyclosporine can improve severe psoriasis, but nephrotoxicity and hypertension are important limitations. Blood-pressure and renal-function monitoring are required; dose and duration need specialist supervision.8

Psoriasis biologics and specialist systemic safety

Psoriasis involves inflammatory immune pathways including IL-23, IL-17 and TNF. For moderate-to-severe disease or significant involvement of difficult sites, systemic therapy may include TNF inhibitors, IL-17 inhibitors, IL-23 inhibitors or IL-12/23 inhibitors, with selection affected by psoriatic arthritis, inflammatory bowel disease, infection risks, prior therapy and local availability.3

Before some biologics or immunosuppressive medicines, clinicians consider tuberculosis, hepatitis screening and vaccination status. IL-17 blockade may warrant caution in inflammatory bowel disease, and all agents have indication-specific adverse effects. Methotrexate is generally weekly, never a routine daily psoriasis tablet, and requires a monitoring plan for blood counts and liver and kidney function.3,7

Acitretin is a systemic retinoid with prolonged reproductive precautions, while cyclosporine can cause hypertension and nephrotoxicity. Biologic therapies do not replace skin care and screening for psoriatic arthritis or cardiometabolic comorbidity.

Anti-infective mechanisms

Agent Mechanism and role
Ketoconazole cream An azole that impairs ergosterol synthesis, rather than simply binding ergosterol. Labelled uses include selected superficial fungal infections and seborrheic dermatitis.9
Acyclovir Viral thymidine kinase helps activate the drug. The triphosphate inhibits viral DNA polymerase and terminates DNA-chain elongation. Its principal action is not inhibition of thymidine kinase.10

Antifungals, antivirals and steroid-modified infections

Topical azoles such as ketoconazole inhibit fungal lanosterol 14-alpha-demethylase, disrupting ergosterol synthesis. They treat selected superficial fungal disease but are not antibiotics against bacteria. Acyclovir requires activation by viral thymidine kinase in infected cells and then interferes with viral DNA polymerase; early treatment in the appropriate herpes infection may be useful, depending on site and severity.9,10

Tinea incognito is a fungal infection with an altered appearance after topical steroid exposure. Using a potent steroid on an undiagnosed scaly rash can suppress redness while allowing infection to persist or spread. When the pattern is atypical or worsening, consider skin scraping, microscopy or appropriate mycologic testing rather than repeatedly increasing steroid potency. Severe cellulitis, rapidly progressive pain or systemic illness needs urgent assessment.

Practical prescribing

Confirm diagnosis, route and formulation; review pregnancy restrictions and set a review date. Assess area and duration for topical corticosteroids and arrange the relevant monitoring for systemic medicines. Persistent or worsening disease warrants reassessment rather than indefinite continuation of ineffective treatment.4,6,7,8

Practical dermatology prescribing checklist

  1. Confirm the diagnosis: eczema, psoriasis, acne, fungus, bacterial infection and viral disease can look similar.
  2. Match vehicle, potency and location: choose ointment, cream, solution or foam based on skin site and tolerance; avoid prolonged very-potent steroid use on thin skin.
  3. Assess age and reproductive safety: topical retinoids, isotretinoin, methotrexate and acitretin carry distinct pregnancy considerations.
  4. Prevent antimicrobial resistance: avoid topical acne antibiotic monotherapy and limit unnecessarily long systemic antibiotic courses.
  5. Plan monitoring: check blood counts and organ function for systemic agents when required and review biologic infection risks.
  6. Set a review date: treatment failure may mean an incorrect diagnosis, poor adherence, a contact allergen or a resistant infection.

Frequently asked questions

Is a stronger steroid always better for a persistent rash?

No. Potency must match the site, diagnosis and duration; fungus can be obscured by steroids.

Can clindamycin be used alone for acne indefinitely?

No. AAD recommends combination approaches including benzoyl peroxide to reduce resistance.11

What did the 2025 AAD atopic dermatitis update add?

It recommended selected use of tapinarof, roflumilast, lebrikizumab and nemolizumab in adults, with indication-specific conditions.1

Is psoriasis methotrexate taken daily?

No. For psoriasis it is generally administered weekly; daily errors can be fatal.7

Can tacrolimus ointment cause systemic steroid atrophy?

It is not a corticosteroid and does not cause steroid-type skin atrophy through glucocorticoid action, although it has other product-specific warnings.5

References

  1. American Academy of Dermatology. Atopic dermatitis clinical guideline [Internet] [cited 2026 Nov 10]. Available from: https://www.aad.org/member/clinical-quality/guidelines/atopic-dermatitis
  2. American Academy of Dermatology. Acne clinical guideline [Internet] [cited 2026 Nov 10]. Available from: https://www.aad.org/member/clinical-quality/guidelines/acne
  3. American Academy of Dermatology. Psoriasis clinical guideline [Internet] [cited 2026 Nov 10]. Available from: https://www.aad.org/member/clinical-quality/guidelines/psoriasis
  4. National Library of Medicine. Clobetasol propionate cream: prescribing information. DailyMed [Internet] [cited 2026 Nov 10]. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1b0e9eb5-71eb-44b4-894a-094a9f325dc8
  5. National Library of Medicine. Tacrolimus ointment: prescribing information. DailyMed [Internet] [cited 2026 Nov 10]. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1bf44a84-14fd-4f80-ad8a-99b1431d631f
  6. National Library of Medicine. Isotretinoin capsules: prescribing information. DailyMed [Internet] [cited 2026 Nov 10]. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31f62a49-4c6d-4ce3-a0ca-d159562370b1
  7. American Academy of Dermatology. Psoriasis treatment: methotrexate [Internet] [cited 2026 Nov 10]. Available from: https://www.aad.org/public/diseases/psoriasis/treatment/medications/methotrexate
  8. American Academy of Dermatology. Psoriasis treatment: cyclosporine [Internet] [cited 2026 Nov 10]. Available from: https://www.aad.org/public/diseases/psoriasis/treatment/medications/cyclosporine
  9. National Library of Medicine. Ketoconazole cream, 2%: prescribing information. DailyMed [Internet] [cited 2026 Nov 10]. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2b3bdb6e-2b48-4979-ae08-bd17cd74130e
  10. National Library of Medicine. Acyclovir cream: prescribing information. DailyMed [Internet] [cited 2026 Nov 10]. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9167ea4a-959d-402c-96b4-619395821c01
  11. American Academy of Dermatology. Guidelines of care for the management of acne vulgaris: recommendations [Internet]. 2024. Available from: AAD clinical guideline [cited 2026 Nov 10].

⚠️ Medical Disclaimer

This article is intended for educational and informational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this article.

The information provided here is based on current scientific literature and established pharmacological principles. However, medical knowledge evolves continuously, and individual patient responses to medications may vary. Healthcare professionals should always use their clinical judgment when applying this information to patient care.

Medical & AI Disclaimer

The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.

We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.

Leave a Reply

Your email address will not be published. Required fields are marked *